

Date Prepared: 3/11/2022

Lorenzo Trippa
Associate Professor
Work Address: 3 Blackfan Circle, 11th Floor, Boston, MA 02215
Email: ltrippa@ds.dfc.harvard.edu

EDUCATION:

Date	Discipline	Degree	Institution
2005	Statistics	M.S. (cum laude)	Bicocca University, Milano, Italy
2009	Statistics	Ph.D	Bocconi University, Milano Italy

POSTDOCTORAL TRAINING:

Dates	Field of Research	Place	Title
2009 - 2011	Biostatistics & Computational Biology	Harvard University, Boston, MA Dana-Farber Cancer Institute, Boston, MA	Postdoctoral Fellow

ACADEMIC APPOINTMENTS:

Dates	Title	Department	Institution
2008 - 2009	Research Intern	Biostatistics	MD Anderson Cancer Center, Houston, TX
2011 - 2017	Assistant Professor	Biostatistics Biostatistics & Computational Biology	Harvard University, Boston, MA Dana-Farber Cancer Institute, Boston, MA
2017 - present	Associate Professor	Biostatistics	Harvard University, Boston MA

	Data Science	Dana-Farber Cancer Institute, Boston, MA
2017 - present	Co-Director of the Program in Regulatory Science	Dana-Farber Cancer Institute, Boston, MA

EVENTS ORGANIZATION

Dates	Event
2016	International Society of Bayesian Analysis meeting
2018	Member of the educational program advisory committee ENAR
2019	Organizer of the workshop <i>Reproducibility in Biomedical Sciences</i> , http://bcb.dfci.harvard.edu/forms/RPMR%20program.pdf

COMMITTEE SERVICE:

DEPARTMENTAL/SCHOOL AND UNIVERSITY SERVICE:

Dates	Name of Committee and Role	Institution/Organization
2014 – 2015, 2021	Colloquium Committee	Harvard T.H. Chan School of Public Health
2015 - 2021	Committee for Admissions to the Doctoral program in Biostatistics	Harvard T.H. Chan School of Public Health

PROFESSIONAL SOCIETIES:

Dates	Role	Society Name
2015 - present	Member	International Society for Bayesian Analysis
2018 - present	Member	International Biometric Society
2019 - present	Member	American Statistical Association

GRANT REVIEW ACTIVITIES:

Dates	Organization
2015	Medical Research Council (www.mrc.ac.uk)
2015	NIH (www.nih.gov , NCI Omnibus announcement)
2016	Medical Research Council (www.mrc.ac.uk)
2016	NIH (www.nih.gov , NINDS)
2018	NIH (www.nih.gov , CSR)

2019	National Science Foundation
2021	NIH (www.nih.gov, NINDS)
2021	Research Grants Council (RGC) of Hong Kong
2022	NIH (Biostatistical Methods and Research Design)

PROTOCOL REVIEWER:

Dates	Name of Committee	Organization
2013 - 2018	Member of the Scientific Review Committee of the Office for Human Research Studies	Dana-Farber Cancer Institute
2015 - 2019	Clinical Trial Data Safety Monitoring Board member: <i>Intraoperative Protective Ventilation and Postoperative Pulmonary Complications</i>	Dana-Farber Cancer Institute
2020 - 2021	Clinical Trial Data Safety Monitoring Board member: <i>Australasian COVID-19 (ASCOT) ADaptive Trial</i>	ASCOT

EDITORIAL ROLES:

Dates	Role	Journal
2016 - present	Associated Editor	SM Journal of Biometrics & Biostatistics
2019 - present	Associated Editor	Trials
2019 - present	Associated Editor	Clinical Trials
2020 - present	Associated Editor	Biometrics
2021 - present	Associated Editor	New England Journal of Statistics and Data Science
2021 - present	Associated Editor	Statistical Science

Ad hoc reviewer:

Annals of Applied Statistics, Bayesian Analysis, Bioinformatics, Biometrics, Biostatistics, BMC Bioinformatics, Clinical Trials, Breast Cancer Research and Treatment, Clinical Trials, Computer Methods and Programs in Biomedicine, Computational Statistics and Data Analysis, JASA, Journal of Computational and Graphical Statistics, Journal of Statistical Planning and Inference Journal of the Royal Statistical Society C, Medical Decision Making, Science, Statistics in Biopharmaceutical Research, Statistics in Biosciences, Statistics in Medicine Statistical Methods and Applications, Statistical Science.

HONORS AND DISTINCTIONS:

Dates	Name of Honor/Distinction	Organization
2009	Savage Award for Ph.D. Thesis	International Society for Bayesian Analysis
2010	Postdoctoral Research Fellowship	American Italian Cancer Foundation
2011	Renewal of the Postdoctoral Research Fellowship	American Italian Cancer Foundation

FUNDED GRANTS:

- 1/1/2012 - 12/31/2013 William F. Milton Fund
Efficacy Measures for Adaptive Phase II Trials in Cancer
Role: PI, 40K
- 1/1/2014 - 12/31/2015 Dana Fund
Control of False Positive Results in Complex Adaptive Clinical Trials
Role: PI, 50K
- 1/1/2014 - 12/31/2015 Wong Family Award
Designing Clinical Studies of Targeted Drugs Across Cancer Modalities
Role: Co-Investigator, PI: William Barry, 80K
- 1/1/2015 - 12/31/2016 Dana Fund
Statistical Methods for Dynamic Clinical Trials
Role: PI, 90K
- 8/2/2015 - 12/31/2017 Claudia Barr Award
Machine Learning and Statistical Methods for Reproducible Research
Role: PI, 220K
- 1/1/2016 - 12/31/2017 Dana Fund
Information-driven designs to evaluate Stereotactic Body Radiation
Role: PI, 30K
- 9/1/2015 - 9/1/2018 Burroughs Wellcome Fund
Development of a Biomarker Enriched Adaptive Trial for Patients with Glioblastoma
PI: Brian Alexander, 500K
Role: Co-Investigator and Primary Statistician of the project
- 1/1/2018 - 12/31/2021 *Encouraging Appropriate Care Using Behavioral Economics through Electronic Health Records, R01-NIH*
PI: Julie Lauffenburger
Role: Co-Investigator
- 7/1/2018 - 7/1/2021 NSF #1810829
Statistical Methods for Multi-Study Predictions
Role: Co-PI with Giovanni Parmigiani, 350K
- 4/1/2019 - 3/31/2020 Candel collaboration (www.advantagene.com)
Design and analysis of the Candel trial
Role: PI, 80K

- 8/1/2019 - 8/1/2020 Project Data Sphere
External Control Arm
(<https://www.projectdatasphere.org/research/programs/external-control-arm>)
Role: PI, 75K
- 8/16/2019 - 7/31/2024 R01CA237414
CDK7 inhibitors as a new strategy to overcome treatment resistance in ER+ metastatic breast cancer
PI: Jeselsohn, R.
Role: Co-Investigator, biostatistical support
- 1/1/2020 -12/31/2023 INTUIT-NF2 trial (<https://www.ctf.org/news/new-nf2-clinical-trial-intuitt-for-nf2>)
PI: Plotkin, Scot
Role: Co-Investigator, biostatistical support
- 4/22/2020 - 4/21/2023 *Nano-SMART: An Adaptive Phase I-II Trial of AGuIX Gadolinium-based Nanoparticles With Stereotactic Magnetic Resonance-guided Adaptive Radiation Therapy in Centrally Located Nonsmall Cell Lung Cancer and Locally Advanced Unresectable Pancreatic Ductal Adenocarcinoma*
PI: Cagney Daniel
Role: Co-Investigator, biostatistical support
- 8/1/2020 - 8/1/2023 Project Data Sphere
External Control Arm
(<https://www.projectdatasphere.org/research/programs/external-control-arm>)
Role: PI, 320K
- 5/1/2021 - 9/1/2022 Candel collaboration (www.advantagene.com)
Design and analysis of the Candel trial
Role: PI, 65K
- 5/1/2021 - 12/31/2024 NIH R01 LM013352-01A1
Statistical Methods and Validation Analyses for the Integration of External Data in Clinical Trials
Role: PI, 1.5M
- 7/1/2021 - 6/30/2024 NSF 87295
Advancing Statistical Methods for Multi-Study Predictions
Role: Co-PI with Giovanni Parmigiani, 350K

TEACHING AND TRAINING:

TEACHING, HARVARD CHAN SCHOOL COURSES

Dates	Course number/Title
-------	---------------------

2012	Probability Theory II, BIO250
2013	Probability Theory II, BIO250
2014	Probability Theory II, BIO250
2015	Probability Theory II, BIO250
2016	Bayesian Statistics, BIO249
2017	Bayesian Statistics, BIO249
2017	HarvardX (edx.org) <i>Principles, Statistical and Computational Tools for Reproducible Science</i> Co-Instructors: Christine Choirat, Curtis Huttenhower, John Quackenbush
2018	Bayesian Statistics, BIO249
2019	Probability Theory II, BIO250
2020	Probability Theory II, BIO250
2021	Probability Theory II, BIO250

SHORT COURSES

Dates	Course number/Title
2/2020	<i>Bayesian adaptive clinical trials</i> , Monash University, Australia
3/2020	<i>Bayesian adaptive clinical trials</i> , NHMRC Clinical Trials Centre, Sidney, Australia

ADVISORY AND SUPERVISORY RESPONSIBILITIES

Dates	Name of Trainee	Type of Supervision
<u>Doctoral Students, Harvard University</u>		
2011 - 2014	Yifan Zhang	PhD student advising <i>(Co-mentored with Giovanni Parmigiani. In her dissertation, Yifan proposed statistical methods for the design and analysis of response-adaptive clinical trials. Co-authored manuscripts: 27,67 in bibliography.)</i>
2014 - 2017	Boyu Ren	PhD student advising <i>(Co-mentored with Curtis Huttenhower. In his dissertation, Boyu introduced new Bayesian nonparametric models for dimension reduction, which were used to analyze microbiome datasets. Co-authored manuscripts: 37,76 in bibliography.)</i>
2016 - 2019	Tom Madsen	PhD student advising <i>(Co-mentored with Franziska Michor. In his dissertation, Tom developed approaches for efficient posterior computations with Mendelian risk assessment models. Co-authored manuscript: 47 in bibliography.)</i>
2017 - 2020	Emma Thomas	PhD student advising <i>(Co-mentored with Francesca Dominici. In her dissertation, Emma studied novel Bayesian regression methods for multi-response models. Co-authored manuscripts: 69,110,111 in bibliography.)</i>
2018 - 2020	Zoe Guan	PhD student advising <i>(Co-mentored with Giovanni Parmigiani and Danielle Braun. In her dissertation, Zoe modeled cancer inheritance and families with multiple cancer diagnoses using neural networks. Co-authored manuscript: 112 in bibliography.)</i>
2018 - 2021	Eric Dunipace	PhD student advising <i>(In his dissertation, Eric studied time-to-event models. He is currently a medical student at the David Geffen School of Medicine at UCLA. He worked also with José R. Zubizarreta.)</i>
2019 - present	Gopal Kotecha	PhD student advising <i>(Gopal's research is focused on factorial designs with applications in the development of combination therapies.)</i>
2020 - present	Larry Han	PhD student advising <i>(In his dissertation work, Larry is introducing metrics and summaries to evaluate the sensitivity of clinical trial operating characteristics to unknown parameters such as the enrollment rate or drop-out decisions. Larry is also mentored by Tianxi Cai.)</i>

2021 - present Lin Wang PhD student advising
(Her work focuses on prediction models for time to event variables. Lin is also mentored by Tianxi Cai.)

Visiting Students

2013 - 2015 Matteo Cellamare PhD advising of visiting students
(Doctoral student at “La Sapienza” University, Rome, Italy. In his dissertation, Matteo studied Bayesian response-adaptive clinical trial designs. Co-authored manuscripts: 31,35,46,55,63,95 in bibliography.)

2014 - 2016 Roberta De Vito PhD advising of visiting students
(Doctoral student at Padua University, Italy, co-advised with Giovanni Parmigiani. In her dissertation, Roberta developed multi-study factor models for high-dimensional data. Co-authored manuscripts: 53,92,114 in bibliography.)

2015 - 2018 Ilaria Domenicano PhD advising of visiting students
(Doctoral student at “La Sapienza” University, Rome, Italy. In her dissertation, Ilaria studied Bayesian dose-finding designs. Co-authored manuscript: 55 in bibliography.)

2017 - 2019 Andrea Arfe’ PhD advising of visiting students
(Doctoral student at Bocconi University, Milan, Italy. In his dissertation, Andrea studied time-to-event models for the analysis of clinical trials. Co-authored manuscripts: 60,75,80,84,97,102 in bibliography.)

2020 - 2022 Marta Bonsaglio PhD advising of visiting students
(Doctoral student at Bocconi University, Milan, Italy. In her dissertation work, Marta is deriving asymptotic results on Bayesian response-adaptive clinical trials. Co-authored manuscript: 108 in bibliography.)

2021 - present Francesco Mariani PhD advising of visiting students
(Doctoral student at “La Sapienza” University, Rome, Italy. His research focuses on phase I clinical trial designs.)

2018 - 2021 Robert Gotmaker PhD students advising at other institutions
(Robert in his dissertation studied adaptive clinical trial designs in pediatrics. Monash University, Australia. Primary advisor: Stephane Heritier. Co-authored manuscript: 56 in bibliography.)

2019 - 2021 Claire Galea PhD students advising at other institutions
(The dissertation focused on multi-stage clinical trial designs. Monash University, Australia. Primary advisor: Stephane Heritier)

Master Students, Harvard University

2015 - 2016 Wenqing Jiang Master Thesis supervisor
(Thesis title: Statistical Methods to Combine Prediction Models.)

PhD Thesis committee member, Harvard University

2012 - 2014 Yifan Zhang PhD Thesis committee member

2013 - 2016 Christina McIntosh PhD Thesis committee member

2013 - 2016 Yared Gurmu PhD Thesis committee member

2015 - 2017 Emma Schwager PhD Thesis committee member

2015 - 2018 Lin Liu PhD Thesis committee member

2016 - 2018 Theo Huang PhD Thesis committee member

2018 - 2018 Matthew Ploenzke PhD Thesis committee member

2018 - 2021 Eric Dunipace PhD Thesis committee member

2020 - present Isabella Grabski PhD Thesis committee member

2020 - present Larry Han PhD Thesis committee member

2020 - present Gopal Kotecha PhD Thesis committee member

Postdoctoral Fellows

2012 - 2015 Steffen Venz Postdoctoral Fellow

2014 - 2016 Prabhani Kuruppumullage Postdoctoral Fellow

2016 - 2018 Matteo Cellamare Postdoctoral Fellow

2018 - present	Alejandra Avalos Pacheco	Postdoctoral Fellow
2019 - present	Massimiliano Russo	Postdoctoral Fellow
2021 - present	Federico Ferrari	Postdoctoral Fellow

SPARC: www.dfhcc.harvard.edu/research/cancer-disparities/students/sparc/

2018	Ana Mikaela Guillen	Undergraduate visiting students
------	---------------------	---------------------------------

INVITED PRESENTATIONS:

Dates	Organization/Location
3/2008	ENAR, Eastern North American Region. International Biometric Society, Arlington, VA
5/2008	MD Anderson Cancer Center, Houston, TX
7/2008	WNAR, Western North American Region of The International Biometric Society. Davis, CA
11/2008	Rice University, Houston, TX
3/2009	ENAR, Eastern North American Region. International Biometric Society. San Antonio, TX
4/2009	New England Statistics Symposium, Boston, MA
8/2009	Joint Statistical Meeting, Washington, DC
4/2010	New England Statistics Symposium, Yale University, New Haven, CT
12/2010	International Conference of the ERCIM on Computational and Methodological Statistics, London, UK
6/2011	8th Workshop on Bayesian Nonparametrics, Veracruz, Mexico
3/2012	10th Annual ASA CT Chapter Mini-Conference, Yale, New Haven, CT
3/2013	ENAR, Eastern North American Region. International Biometric Society, Orlando, FL
4/2013	New England Statistics Symposium, Storrs, CT
6/2013	9th Conference on Bayesian Nonparametrics, Amsterdam, Netherlands
7/2013	ASTRO Annual Meeting, Atlanta, GA
1/2014	ISBA Regional Meeting at Varanasi, Varanasi, India
4/2014	New England Statistics Symposium, Harvard School of Public Health, Boston, MA
8/2014	Joint Statistical Meetings, Boston, MA
10/2014	Duke University, Department of Biostatistics, Durham, NC
10/2014	Memorial Sloan Kettering Cancer Center, Department of Biostatistics, New York, NY
11/2014	Texas A&M University, Department of Statistics, College Station, TX
1/2015	McGill University, Department of Biostatistics, Montreal, Canada
1/2015	University of North Carolina Chapel Hill, Department of Biostatistics, Chapel Hill, NC
3/2015	Columbia University, Department of Biostatistics, New York, NY
3/2015	AACR Annual Meeting, Philadelphia, PA
4/2015	New England Statistics Symposium, Yale University, New Haven, CT
4/2016	ICSA Applied Statistics Symposium, Fort Collins, CO

1/2016 UMass Medical School in Worcester, Department of Biostatistics, Worcester, MA
6/2016 Bocconi University, Department of Decision Sciences, Milan, Italy
8/2016 Symposium on Statistical Methods for Pharmacogenetic Epidemiology of Cancer, Memorial Sloan Kettering Cancer Center, New York City, NY
6/2017 BISP9 - 9th Bayesian Inference in Stochastic Processes Workshop, Milan, Italy
6/2017 11th Conference on Bayesian Nonparametrics, Paris, France
8/2017 Joint Statistical Meetings, Baltimore, MD
3/2018 Biomarker Summit, San Diego, Bayesian Uncertainty-Directed Dose Finding Designs
3/2018 The Third ISBA-EAC Conference, Seoul, South Korea, Bayesian Uncertainty-Directed Dose Finding Designs
4/2018 ISBA, Edinburgh, Bayesian uncertainty directed trial designs
5/2018 The 2nd OncoStat Symposium, The University of Chicago, Bayesian uncertainty directed trial designs
6/2018 JSM, Vancouver, Canada, Bayesian uncertainty directed trial designs
2/2019 Department of Statistics & Data Science - The University of Texas at Austin
2/2019 MD Anderson Cancer Center, Dep. Biostatistics
3/2019 AACR Annual Meeting
4/2019 Harvard-MIT Center for Regulatory Science
7/2019 Networking International Biometric Society, Napoly, Italy
7/2019 Seminar at CNR, Milan, Italy
7/2019 Acop meeting, Orlando, FL
10/2019 iBRIGHT conference, Houston, TX
2/2020 JSM meeting, Online
11/2020 University of Michigan, Department of Biostatistics, Seminar
11/2020 McGill University, Department of Biostatistics, Seminar
12/2020 ICSA conference
3/2021 John Hopkins, Causal Inference Seminars
3/2021 NISS Ingram Olkin Forum
4/2021 ASA Biopharma workshop
5/2021 MD Anderson Cancer Center - Biostatistics
6/2021 Society for Neuro-Oncology Annual Scientific Meeting
6/2021 DFCI, Frontiers in Biostatistics
12/2021 New England Statistics Symposium
12/2021 International Biometric Society

BIBLIOGRAPHY:

1. TRIPPA, L., AND MULIERE, P. Bayesian nonparametric binary regression via random tessellations. *Statistics & probability letters* 79, 21 (2009), 2273–2280
2. TRIPPA, L., BULLA, P., AND PETRONE, S. Extended bernstein prior via reinforced urn processes. *Annals of the Institute of Statistical Mathematics* 63, 3 (2011), 481–496
3. TRIPPA, L., MÜLLER, P., AND JOHNSON, W. The multivariate beta process and an extension of the polya tree model. *Biometrika* 98, 1 (2011), 17–34

4. TRIPPA, L., AND PARMIGIANI, G. False discovery rates in somatic mutation studies of cancer. *The Annals of Applied Statistics* (2011), 1360–1378
5. TRIPPA, L., LEE, E. Q., WEN, P. Y., BATCHELOR, T. T., CLOUGHESY, T., PARMIGIANI, G., AND ALEXANDER, B. M. Bayesian adaptive randomized trial design for patients with recurrent glioblastoma. *Journal of Clinical Oncology* 30, 26 (2012), 3258
6. TRIPPA, L., AND FAVARO, S. A class of normalized random measures with an exact predictive sampling scheme. *Scandinavian Journal of Statistics* 39, 3 (2012), 444–460
7. TRIPPA, L., ROSNER, G. L., AND MÜLLER, P. Bayesian enrichment strategies for randomized discontinuation trials. *Biometrics* 68, 1 (2012), 203–211
8. DING, J., TRIPPA, L., ZHONG, X., AND PARMIGIANI, G. Hierarchical bayesian analysis of somatic mutation data in cancer. *The Annals of Applied Statistics* (2013), 883–903
9. BACALLADO, S., FAVARO, S., AND TRIPPA, L. Bayesian nonparametric analysis of reversible markov chains. *The Annals of Statistics* (2013), 870–896
10. LEE, J., QUINTANA, F. A., MÜLLER, P., AND TRIPPA, L. Defining predictive probability functions for species sampling models. *Statistical Science* 28, 2 (2013), 209
11. ALEXANDER, B. M., WEN, P. Y., TRIPPA, L., REARDON, D. A., YUNG, W.-K. A., PARMIGIANI, G., AND BERRY, D. A. Biomarker-based adaptive trials for patients with glioblastoma—lessons from i-spy 2. *Neuro-oncology* 15, 8 (2013), 972–978
12. WADE, S., DUNSON, D. B., PETRONE, S., AND TRIPPA, L. Improving prediction from dirichlet process mixtures via enrichment. *The Journal of Machine Learning Research* 15, 1 (2014), 1041–1071
13. RIESTER, M., WEI, W., WALDRON, L., CULHANE, A. C., TRIPPA, L., OLIVA, E., KIM, S.-H., MICHOR, F., HUTTENHOWER, C., PARMIGIANI, G., AND BIRRER, M. J. Risk prediction for late-stage ovarian cancer by meta-analysis of 1525 patient samples. *J Natl Cancer Inst* 106, 5 (Apr 2014)
14. ALEXANDER, B. M., AND TRIPPA, L. Progression-free survival: too much risk, not enough reward. *Neuro oncology* 16, 5 (2014), 615–616
15. WASON, J. M., AND TRIPPA, L. A comparison of bayesian adaptive randomization and multi-stage designs for multi-arm clinical trials. *Statistics in medicine* 33, 13 (2014), 2206–2221
16. BERNAU, C., RIESTER, M., BOULESTEIX, A.-L., PARMIGIANI, G., HUTTENHOWER, C., WALDRON, L., AND TRIPPA, L. Cross-study validation for the assessment of prediction algorithms. *Bioinformatics* 30, 12 (2014), i105–i112(LW and LT co-last authors)
17. MARCO, E., KARP, R. L., GUO, G., ROBSON, P., HART, A. H., TRIPPA, L., AND YUAN, G.-C. Bifurcation analysis of single-cell gene expression data reveals epigenetic landscape. *Proceedings of the National Academy of Sciences* 111, 52 (2014), E5643–E5650
18. BOURGEOIS, E. B., JOHNSON, B. N., MCCOY, A. J., TRIPPA, L., COHEN, A. S., AND MARSH, E. D. A toolbox for spatiotemporal analysis of voltage-sensitive dye imaging data in brain slices. *PLoS One* 9, 9 (2014), e108686
19. ALEXANDER, B. M., GALANIS, E., YUNG, W. K. A., BALLMAN, K. V., BOYETT, J. M., CLOUGHESY, T. F., DEGROOT, J. F., HUSE, J. T., MANN, B., MASON, W., MELLINGHOFF, I. K., MIKKELSEN, T., MISCHER, P. S., O’NEILL, B. P., PRADOS, M. D., SARKARIA, J. N., TAWAB-AMIRI, A., TRIPPA, L., YE, X., LIGON, K. L., BERRY, D. A., AND WEN, P. Y. Brain malignancy steering committee clinical trials

- planning workshop: report from the targeted therapies working group. *Neuro Oncol* 17, 2 (Feb 2015), 180–188
20. ALEXANDER, B. M., AND TRIPPA, L. Getting it first versus getting it right: Weighing the value of and evidence for progression-free survival as a surrogate endpoint for overall survival in glioblastoma. *Neuro-oncology* 17, 5 (2015), 765–766
 21. TRIPPA, L., WALDRON, L., HUTTENHOWER, C., AND PARMIGIANI, G. Bayesian nonparametric cross-study validation of prediction methods. *The Annals of Applied Statistics* 9, 1 (2015), 402–428
 22. VENTZ, S., AND TRIPPA, L. Bayesian designs and the control of frequentist characteristics: a practical solution. *Biometrics* 71, 1 (2015), 218–226
 23. BACALLADO, S., FAVARO, S., AND TRIPPA, L. Looking-backward probabilities for gibbs-type exchangeable random partitions. *Bernoulli* 21, 1 (2015), 1–37
 24. BACALLADO, S., FAVARO, S., AND TRIPPA, L. Bayesian nonparametric inference for shared species richness in multiple populations. *Journal of Statistical Planning and Inference* 166 (2015), 14–23
 25. RAMKISSOON, S. H., BI, W. L., SCHUMACHER, S. E., RAMKISSOON, L. A., HAIDAR, S., KNOFF, D., DUBUC, A., BROWN, L., BURNS, M., CRYAN, J. B., ABEDALTHAGAFI, M., KANG, Y. J., SCHULTZ, N., REARDON, D. A., LEE, E. Q., RINNE, M. L., NORDEN, A. D., NAYAK, L., RULAND, S., DOHERTY, L. M., LAFRANKIE, D. C., HORVATH, M., AIZER, A. A., RUSSO, A., ARVOLD, N. D., CLAUS, E. B., AL-MEFTY, O., JOHNSON, M. D., GOLBY, A. J., DUNN, I. F., CHIOCCA, E. A., TRIPPA, L., SANTAGATA, S., FOLKERTH, R. D., KANTOFF, P., ROLLINS, B. J., LINDEMAN, N. I., WEN, P. Y., LIGON, A. H., BEROUKHIM, R., ALEXANDER, B. M., AND LIGON, K. L. Clinical implementation of integrated whole-genome copy number and mutation profiling for glioblastoma. *Neuro Oncol* 17, 10 (Oct 2015), 1344–1355
 26. TRIPPA, L., WEN, P. Y., PARMIGIANI, G., BERRY, D. A., AND ALEXANDER, B. M. Combining progression-free survival and overall survival as a novel composite endpoint for glioblastoma trials. *Neuro-oncology* 17, 8 (2015), 1106–1113
 27. ZHANG, Y., TRIPPA, L., AND PARMIGIANI, G. Optimal bayesian adaptive trials when treatment efficacy depends on biomarkers. *Biometrics* 72, 2 (2016), 414–421
 28. BACALLADO, S., PANDE, V., FAVARO, S., AND TRIPPA, L. Bayesian regularization of the length of memory in reversible sequences. *Journal of the Royal Statistical Society: Series B (Statistical Methodology)* 78, 4 (2016), 933–946
 29. ANTONELLI, J., TRIPPA, L., AND HANEUSE, S. Mitigating bias in generalized linear mixed models: The case for bayesian nonparametrics. *Statistical Science* 31, 1 (2016), 80
 30. GIECOLD, G., MARCO, E., GARCIA, S. P., TRIPPA, L., AND YUAN, G.-C. Robust lineage reconstruction from high-dimensional single-cell data. *Nucleic acids research* 44, 14 (2016), e122–e122
 31. CELLAMARE, M., MILSTEIN, M., VENTZ, S., BAUDIN, E., TRIPPA, L., AND MITNICK, C. Bayesian adaptive randomization in a clinical trial to identify new regimens for mdr-tb: the endtb trial. *The International Journal of Tuberculosis and Lung Disease* 20, 12 (2016), S8–S12 (CM and LT co-last authors)
 32. ZHAO, L., CLAGGETT, B., TIAN, L., UNO, H., PFEFFER, M. A., SOLOMON, S. D., TRIPPA, L., AND WEI, L. On the restricted mean survival time curve in survival analysis. *Biometrics* 72, 1 (2016), 215–221

33. XU, Y., TRIPPA, L., MÜLLER, P., AND JI, Y. Subgroup-based adaptive (suba) designs for multi-arm biomarker trials. *Statistics in Biosciences* 8, 1 (2016), 159–180
34. TRIPPA, L., AND ALEXANDER, B. M. Bayesian baskets: a novel design for biomarker-based clinical trials. *Journal of Clinical Oncology* (2016), JCO–2016
35. CELLAMARE, M., VENTZ, S., BAUDIN, E., MITNICK, C. D., AND TRIPPA, L. A bayesian response-adaptive trial in tuberculosis: the endtb trial. *Clinical Trials* 14, 1 (2017), 17–28
36. JO, S., LEE, J., MÜLLER, P., QUINTANA, F. A., AND TRIPPA, L. Dependent species sampling models for spatial density estimation. *Bayesian Analysis* 12, 2 (2017), 379–406
37. REN, B., BACALLADO, S., FAVARO, S., HOLMES, S., AND TRIPPA, L. Bayesian nonparametric ordination for the analysis of microbial communities. *Journal of the American Statistical Association* 112, 520 (2017), 1430–1442
38. VENTZ, S., PARMIGIANI, G., AND TRIPPA, L. Combining bayesian experimental designs and frequentist data analyses: motivations and examples. *Applied Stochastic Models in Business and Industry* 33, 3 (2017), 302–313
39. BACALLADO, S., BATTISTON, M., FAVARO, S., AND TRIPPA, L. Sufficiency postulates for gibbs-type priors and hierarchical generalizations. *Statistical Science* (2017), 487–500
40. BOWDEN, J., AND TRIPPA, L. Unbiased estimation for response adaptive clinical trials. *Statistical methods in medical research* 26, 5 (2017), 2376–2388
41. MANIER, S., LIU, C.-J., AVET-LOISEAU, H., PARK, J., SHI, J., CAMPIGOTTO, F., SALEM, K. Z., HUYNH, D., GLAVEY, S. V., RIVOTTO, B., SACCO, A., ROCCARO, A. M., BOUYSSOU, J., MINVIELLE, S., MOREAU, P., FACON, T., LELEU, X., WELLER, E., TRIPPA, L., AND GHOBRIAL, I. M. Prognostic role of circulating exosomal mirnas in multiple myeloma. *Blood* 129, 17 (Apr 2017), 2429–2436
42. VENTZ, S., BARRY, W. T., PARMIGIANI, G., AND TRIPPA, L. Bayesian response-adaptive designs for basket trials. *Biometrics* 73, 3 (2017), 905–915
43. VENTZ, S., ALEXANDER, B. M., PARMIGIANI, G., GELBER, R. D., AND TRIPPA, L. Designing clinical trials that accept new arms: an example in metastatic breast cancer. *Journal of Clinical Oncology* 35, 27 (2017), 3160–3168
44. TANGUTURI, S. K., TRIPPA, L., RAMKISSOON, S. H., PELTON, K., KNOFF, D., SANDAK, D., LINDEMAN, N. I., LIGON, A. H., BEROUKHIM, R., PARMIGIANI, G., WEN, P. Y., LIGON, K. L., AND ALEXANDER, B. M. Leveraging molecular datasets for biomarker-based clinical trial design in glioblastoma. *Neuro Oncol* 19, 7 (Jul 2017), 908–917
45. FRIEDMAN, A., XIA, Y., TRIPPA, L., LE, L., IGRAS, V., FREDERICK, D., WARGO, J., TANABE, K., LAWRENCE, D., NEUBERG, D., FLAHERTY, K., AND FISHER, D. Feasibility of ultra-high-throughput functional screening of melanoma biopsies for discovery of novel cancer drug combinations. *Clinical Cancer Research* 23, 16 (2017), 4680–4692
46. VENTZ, S., CELLAMARE, M., PARMIGIANI, G., AND TRIPPA, L. Adding experimental arms to platform clinical trials: randomization procedures and interim analyses. *Biostatistics* 19, 2 (2018), 199–215
47. MADSEN, T., BRAUN, D., PENG, G., PARMIGIANI, G., AND TRIPPA, L. Efficient computation of the joint probability of multiple inherited risk alleles from pedigree data. *Genetic epidemiology* 42, 6 (2018), 528–538

48. O'DONNELL, E. K., LAUBACH, J. P., YEE, A. J., CHEN, T., HUFF, C. A., BASILE, F. G., WADE, P. M., PABA-PRADA, C. E., GHOBRIAL, I. M., SCHLOSSMAN, R. L., BURKE, J. N., HARRINGTON, C. C., LIVELY, K. J., LYONS, H. F., MUNSHI, N. C., ANDERSON, K. C., TRIPPA, L., RICHARDSON, P. G., AND RAJE, N. S. A phase 2 study of modified lenalidomide, bortezomib and dexamethasone in transplant-ineligible multiple myeloma. *Br J Haematol* 182, 2 (Jul 2018), 222–230
49. VENTZ, S., ALEXANDER, B. M., AND TRIPPA, L. Bayesian adaptive randomization in dose-finding trials. *JAMA network open* 1, 8 (2018), e186075–e186075
50. SKLAVENTIS-PISTOFIDIS, R., CAPELLETTI, M., LIU, C.-J., REIDY, M., ZAVIDIJ, O., HUYNH, D., HENRICK, P., SAVELL, A., REYES, K., RIVOTTO, B., BUSTOROS, M., PERILLA-GLEN, A., TRIPPA, L., CASTILLO, J. J., TREON, S. P., AND GHOBRIAL, I. M. Bortezomib overcomes the negative impact of cxc4 mutations on survival of waldenstrom macroglobulinemia patients. *Blood* 132, 24 (Dec 2018), 2608–2612
51. ALEXANDER, B. M., SCHOENFELD, J. D., AND TRIPPA, L. Hazards of hazard ratios-deviations from model assumptions in immunotherapy. *The New England journal of medicine* 378, 12 (2018), 1158–1159
52. VANDERBEEK, A. M., RAHMAN, R., FELL, G., VENTZ, S., CHEN, T., REDD, R., PARMIGIANI, G., CLOUGHESY, T. F., WEN, P. Y., TRIPPA, L., AND ALEXANDER, B. M. The clinical trials landscape for glioblastoma: is it adequate to develop new treatments? *Neuro Oncol* 20, 8 (Jul 2018), 1034–1043(BA and LT co-last authors)
53. DE VITO, R., BELLIO, R., TRIPPA, L., AND PARMIGIANI, G. Multi-study factor analysis. *Biometrics* 75, 1 (2019), 337–346
54. RAHMAN, R., VENTZ, S., FELL, G., VANDERBEEK, A., TRIPPA, L., AND ALEXANDER, B. M. Divining responder populations from survival data. *Annals of Oncology* 30, 6 (2019), 1005–1013
55. DOMENICANO, I., VENTZ, S., CELLAMARE, M., MAK, R., AND TRIPPA, L. Bayesian uncertainty-directed dose finding designs. *Journal of the Royal Statistical Society: Series C (Applied Statistics)* 68, 5 (2019), 1393–1410
56. GOTMAKER, R., BARRINGTON, M. J., REYNOLDS, J., TRIPPA, L., AND HERITIER, S. Bayesian adaptive design: the future for regional anesthesia trials? *Regional Anesthesia & Pain Medicine* (2019)
57. BUSTOROS, M., SKLAVENTIS-PISTOFIDIS, R., KAPOOR, P., LIU, C.-J., KASTRITIS, E., ZANWAR, S., FELL, G., ABEYKOON, J. P., HORNBURG, K., NEUSE, C. J., MARINAC, C. R., LIU, D., SOIFFER, J., GAVRIATOPOULOU, M., BOEHNER, C., CAPPUCIO, J. M., DUMKE, H., REYES, K., SOIFFER, R. J., KYLE, R. A., TREON, S. P., CASTILLO, J. J., DIMOPOULOS, M. A., ANSELL, S. M., TRIPPA, L., AND GHOBRIAL, I. M. Progression risk stratification of asymptomatic waldenström macroglobulinemia. *Journal of Clinical Oncology* 37, 16 (2019), 1403–1411. PMID: 30990729
58. ALEXANDER, B. M., TRIPPA, L., GAFFEY, S., ARRILLAGA-ROMANY, I. C., LEE, E. Q., RINNE, M. L., AHLUWALIA, M. S., COLMAN, H., FELL, G., GALANIS, E., DE GROOT, J., DRAPPATZ, J., LASSMAN, A. B., MEREDITH, D. M., NABORS, L. B., SANTAGATA, S., SCHIFF, D., WELCH, M. R., LIGON, K. L., AND WEN, P. Y. Individualized screening trial of innovative glioblastoma therapy (insight): A bayesian adaptive platform trial to develop precision medicines for patients with glioblastoma. *JCO Precis Oncol* 3 (2019)(BA and LT co-first authors)
59. GHOBRIAL, I. M., LIU, C.-J., ZAVIDIJ, O., AZAB, A. K., BAZ, R., LAUBACH, J. P., MISHIMA, Y., ARMAND, P., MUNSHI, N. C., BASILE, F., CONSTANTINE, M., VREDENBURGH, J., BORUCHOV, A.,

- CRILLEY, P., HENRICK, P. M., HORNBERG, K. T. V., LEBLEBIAN, H., CHUMA, S., REYES, K., NOONAN, K., WARREN, D., SCHLOSSMAN, R., PABA-PRADA, C., ANDERSON, K. C., WELLER, E., TRIPPA, L., SHAIN, K., AND RICHARDSON, P. G. Phase i/ii trial of the cxcr4 inhibitor plerixafor in combination with bortezomib as a chemosensitization strategy in relapsed/refractory multiple myeloma. *Am J Hematol* 94, 11 (Nov 2019), 1244–1253
60. RAHMAN, R., FELL, G., VENTZ, S., ARFÉ, A., VANDERBEEK, A. M., TRIPPA, L., AND ALEXANDER, B. M. Deviation from the proportional hazards assumption in randomized phase 3 clinical trials in oncology: prevalence, associated factors, and implications. *Clinical Cancer Research* 25, 21 (2019), 6339–6345(BA and LT co-last authors)
61. GOEL, S., PERNAS, S., TAN-WASIELEWSKI, Z., BARRY, W. T., BARDIA, A., REES, R., ANDREWS, C., TAHARA, R. K., TRIPPA, L., MAYER, E. L., WINER, E. P., SPRING, L. M., AND TOLANEY, S. M. Ribociclib plus trastuzumab in advanced her2-positive breast cancer: Results of a phase 1b/2 trial. *Clin Breast Cancer* 19, 6 (Dec 2019), 399–404
62. EXMAN, P., GARRIDO-CASTRO, A. C., HUGHES, M. E., FREEDMAN, R. A., LI, T., TRIPPA, L., BYCHKOVSKY, B. L., BARROSO-SOUSA, R., DI LASCIO, S., MACKICHAN, C., LLOYD, M. R., KREVALIN, M., CERAMI, E., MERRILL, M. S., SANTIAGO, R., CROWLEY, L., KUHNLY, N., FILES, J., LINDEMAN, N. I., MACCONAILL, L. E., KUMARI, P., TOLANEY, S. M., KROP, I. E., BOSE, R., JOHNSON, B. E., MA, C. X., DILLON, D. A., WINER, E. P., WAGLE, N., AND LIN, N. U. Identifying erbb2 activating mutations in her2-negative breast cancer: Clinical impact of institute-wide genomic testing and enrollment in matched therapy trials. *JCO Precis Oncol* 3 (2019)
63. VENTZ, S., CELLAMARE, M., BACALLADO, S., AND TRIPPA, L. Bayesian uncertainty directed trial designs. *Journal of the American Statistical Association* 114, 527 (2019), 962–974
64. VENTZ, S., LAI, A., CLOUGHESY, T. F., WEN, P. Y., TRIPPA, L., AND ALEXANDER, B. M. Design and evaluation of an external control arm using prior clinical trials and real-world data. *Clinical Cancer Research* 25, 16 (2019), 4993–5001(BA and LT co-last authors)
65. ANGUS, D. C., ALEXANDER, B. M., BERRY, S., BUXTON, M., LEWIS, R., PAOLONI, M., WEBB, S. A. R., ARNOLD, S., BARKER, A., BERRY, D. A., BONTEN, M. J. M., BROPHY, M., BUTLER, C., CLOUGHESY, T. F., DERDE, L. P. G., ESSERMAN, L. J., FERGUSON, R., FIORE, L., GAFFEY, S. C., GAZIANO, J. M., GIUSTI, K., GOOSSENS, H., HERITIER, S., HYMAN, B., KRAMS, M., LARHOLT, K., LAVANGE, L. M., LAVORI, P., LO, A. W., LONDON, A. J., MANAX, V., MCARTHUR, C., O’NEILL, G., PARMIGIANI, G., PERLMUTTER, J., PETZOLD, E. A., RITCHIE, C., ROWAN, K. M., SEYMOUR, C. W., SHAPIRO, N. I., SIMEONE, D. M., SMITH, B., SPELLBERG, B., STERN, A. D., TRIPPA, L., TRUSHEIM, M., VIELE, K., WEN, P. Y., WOODCOCK, J., AND COALITION, T. A. P. T. Adaptive platform trials: definition, design, conduct and reporting considerations. *Nature Reviews Drug Discovery* 18, 10 (2019), 797–807
66. VANDERBEEK, A. M., VENTZ, S., RAHMAN, R., FELL, G., CLOUGHESY, T. F., WEN, P. Y., TRIPPA, L., AND ALEXANDER, B. M. To randomize, or not to randomize, that is the question: using data from prior clinical trials to guide future designs. *Neuro-oncology* 21, 10 (2019), 1239–1249(BA and LT co-last authors)
67. ZHANG, Y., TRIPPA, L., AND PARMIGIANI, G. Frequentist operating characteristics of bayesian optimal designs via simulation. *Statistics in medicine* 38, 21 (2019), 4026–4039
68. VENTZ, S., TRIPPA, L., AND SCHOENFELD, J. D. Lessons learned from deescalation trials in favorable risk hpv-associated squamous cell head and neck cancer—a perspective on future trial designs. *Clinical Cancer Research* 25, 24 (2019), 7281–7286(JS and LT co-last authors)

69. THOMAS, E. G., TRIPPA, L., PARMIGIANI, G., AND DOMINICI, F. Estimating the effects of fine particulate matter on 432 cardiovascular diseases using multi-outcome regression with tree-structured shrinkage. *Journal of the American Statistical Association* 115, 532 (2020), 1689–1699
70. LEONE, J., DUDA, D. G., HU, J., BARRY, W. T., TRIPPA, L., GERSTNER, E. R., JAIN, R. K., TAN, S., LAWLER, E., WINER, E. P., LIN, N. U., AND TOLANEY, S. M. A phase ii study of cabozantinib alone or in combination with trastuzumab in breast cancer patients with brain metastases. *Breast Cancer Res Treat* 179, 1 (Jan 2020), 113–123
71. BARROSO-SOUSA, R., KROP, I. E., TRIPPA, L., TAN-WASIELEWSKI, Z., LI, T., OSMANI, W., ANDREWS, C., DILLON, D., RICHARDSON, E. T. R., PASTORELLO, R. G., WINER, E. P., MITTENDORF, E. A., BELLON, J. R., SCHOENFELD, J. D., AND TOLANEY, S. M. A phase ii study of pembrolizumab in combination with palliative radiotherapy for hormone receptor-positive metastatic breast cancer. *Clin Breast Cancer* 20, 3 (Jun 2020), 238–245
72. VAZ-LUIS, I., BARROSO-SOUSA, R., DI MEGLIO, A., HU, J., REES, R., SINCLAIR, N., MILISITS, L., LEONE, J. P., CONSTANTINE, M., FAGGEN, M., BRICCETTI, F., BLOCK, C., O’NEIL, K., PARTRIDGE, A., BURSTEIN, H., WAKS, A. G., TRIPPA, L., TOLANEY, S. M., HASSETT, M., WINER, E. P., AND LIN, N. U. Avoiding peg-filgrastim prophylaxis during the paclitaxel portion of the dose-dense doxorubicin-cyclophosphamide and paclitaxel regimen: A prospective study. *J Clin Oncol* 38, 21 (Jul 2020), 2390–2397
73. SCHOENFELD, J. D., FELL, G., HADDAD, R. I., AND TRIPPA, L. Keynote 48: Is it really for everyone? *Oral Oncol* 105, 104762 (2020), 10–1016
74. PARSONS, H. A., RHOADES, J., REED, S. C., GYDUSH, G., RAM, P., EXMAN, P., XIONG, K., LO, C. C., LI, T., FLEHARTY, M., KIRKNER, G. J., ROTEM, D., COHEN, O., YU, F., FITARELLI-KIEHL, M., LEONG, K. W., HUGHES, M. E., ROSENBERG, S. M., COLLINS, L. C., MILLER, K. D., BLUMENSTIEL, B., TRIPPA, L., CIBULSKIS, C., NEUBERG, D. S., DEFELICE, M., FREEMAN, S. S., LENNON, N. J., WAGLE, N., HA, G., STOVER, D. G., CHOUDHURY, A. D., GETZ, G., WINER, E. P., MEYERSON, M., LIN, N. U., KROP, I., LOVE, J. C., MAKRIGIORGOS, G. M., PARTRIDGE, A. H., MAYER, E. L., GOLUB, T. R., AND ADALSTEINSSON, V. A. Sensitive detection of minimal residual disease in patients treated for early-stage breast cancer. *Clin Cancer Res* 26, 11 (Jun 2020), 2556–2564
75. SPRING, L. M., FELL, G., ARFE, A., SHARMA, C., GREENUP, R., REYNOLDS, K. L., SMITH, B. L., ALEXANDER, B., MOY, B., ISAKOFF, S. J., PARMIGIANI, G., TRIPPA, L., AND BARDIA, A. Pathologic complete response after neoadjuvant chemotherapy and impact on breast cancer recurrence and survival: A comprehensive meta-analysis. *Clin Cancer Res* 26, 12 (Jun 2020), 2838–2848 (AB and LT co-last authors)
76. REN, B., BACALLADO, S., FAVARO, S., VATANEN, T., HUTTENHOWER, C., AND TRIPPA, L. Bayesian mixed effects models for zero-inflated compositions in microbiome data analysis. *The Annals of Applied Statistics* 14, 1 (2020), 494–517
77. TABRIZI, S., TRIPPA, L., CAGNEY, D., TANGUTURI, S., VENTZ, S., FELL, G., WEN, P. Y., ALEXANDER, B. M., AND RAHMAN, R. A quantitative framework for modeling covid-19 risk during adjuvant therapy using published randomized trials of glioblastoma in the elderly. *Neuro-oncology* 22, 7 (2020), 918–927
78. METZGER FILHO, O., LEONE, J. P., LI, T., TAN-WASIELEWSKI, Z., TRIPPA, L., BARRY, W. T., YOUNGER, J., LAWLER, E., WALKER, L., FREEDMAN, R. A., TOLANEY, S. M., KROP, I., WINER, E. P.,

- AND LIN, N. U. Phase i dose-escalation trial of tucatinib in combination with trastuzumab in patients with her2-positive breast cancer brain metastases. *Ann Oncol* 31, 9 (Sep 2020), 1231–1239
79. BUSTOROS, M., SKLAVENTIS-PISTOFIDIS, R., PARK, J., REDD, R., ZHITOMIRSKY, B., DUNFORD, A. J., SALEM, K., TAI, Y.-T., ANAND, S., MOUHIEDDINE, T. H., CHAVDA, S. J., BOEHNER, C., ELAGINA, L., NEUSE, C. J., CHA, J., RAHMAT, M., TAYLOR-WEINER, A., VAN ALLEN, E., KUMAR, S., KASTRITIS, E., LESHCHINER, I., MORGAN, E. A., LAUBACH, J., CASNEUF, T., RICHARDSON, P., MUNSHI, N. C., ANDERSON, K. C., TRIPPA, L., AGUET, F., STEWART, C., DIMOPOULOS, M.-A., YONG, K., BERGSAGEL, P. L., MANIER, S., GETZ, G., AND GHOBRIAL, I. M. Genomic profiling of smoldering multiple myeloma identifies patients at a high risk of disease progression. *J Clin Oncol* 38, 21 (Jul 2020), 2380–2389
80. ARFÈ, A., VENTZ, S., AND TRIPPA, L. Shared and usable data from phase 1 oncology trials—“an unmet need. *JAMA oncology* 6, 7 (2020), 980–981
81. RAHMAN, R., TRIPPA, L., ALDEN, S., FELL, G., ABBASI, T., MUNDKUR, Y., SINGH, N. K., TALAWDEKAR, A., HUSAIN, Z., VALI, S., LIGON, K. L., WEN, P. Y., AND ALEXANDER, B. M. Prediction of outcomes with a computational biology model in newly diagnosed glioblastoma patients treated with radiation therapy and temozolomide. *Int J Radiat Oncol Biol Phys* 108, 3 (Nov 2020), 716–724
82. MOUHIEDDINE, T. H., SPERLING, A. S., REDD, R., PARK, J., LEVENTHAL, M., GIBSON, C. J., MANIER, S., NASSAR, A. H., CAPELLETTI, M., HUYNH, D., BUSTOROS, M., SKLAVENTIS-PISTOFIDIS, R., TAHRI, S., HORNBERG, K., DUMKE, H., ITANI, M. M., BOEHNER, C. J., LIU, C.-J., ALDUBAYAN, S. H., REARDON, B., VAN ALLEN, E. M., KEATS, J. J., STEWART, C., MEHR, S., AUCLAIR, D., SCHLOSSMAN, R. L., MUNSHI, N. C., ANDERSON, K. C., STEENSMA, D. P., LAUBACH, J. P., RICHARDSON, P. G., RITZ, J., EBERT, B. L., SOIFFER, R. J., TRIPPA, L., GETZ, G., NEUBERG, D. S., AND GHOBRIAL, I. M. Clonal hematopoiesis is associated with adverse outcomes in multiple myeloma patients undergoing transplant. *Nat Commun* 11, 1 (Jun 2020), 2996
83. MAYER, E. L., ABRAMSON, V., JANKOWITZ, R., FALKSON, C., MARCOM, P. K., TRAINA, T., CAREY, L., RIMAWI, M., SPECHT, J., MILLER, K., STEARNS, V., TUNG, N., PEROU, C., RICHARDSON, A. L., COMPONESCHI, K., TRIPPA, L., TAN-WASIELEWSKI, Z., TIMMS, K., KROP, I., WOLFF, A. C., AND WINER, E. P. Tbcrc 030: a phase ii study of preoperative cisplatin versus paclitaxel in triple-negative breast cancer: evaluating the homologous recombination deficiency (hrd) biomarker. *Ann Oncol* 31, 11 (Nov 2020), 1518–1525
84. ARFÈ, A., FELL, G., ALEXANDER, B., AWAD, M. M., RODIG, S. J., TRIPPA, L., AND SCHOENFELD, J. D. Meta-analysis of pd-11 expression as a predictor of survival after checkpoint blockade. *JCO Precision Oncology* 4 (2020), 1196–1206 (JS and LT co-last authors)
85. VENTZ, S., MAZUMDER, R., AND TRIPPA, L. Integration of survival data from multiple studies. *Biometrics* (2020)
86. TOLANEY, S. M., BARROSO-SOUSA, R., KEENAN, T., LI, T., TRIPPA, L., VAZ-LUIS, I., WULF, G., SPRING, L., SINCLAIR, N. F., ANDREWS, C., PITTENGER, J., RICHARDSON, E. T. R., DILLON, D., LIN, N. U., OVERMOYER, B., PARTRIDGE, A. H., VAN ALLEN, E., MITTENDORF, E. A., WINER, E. P., AND KROP, I. E. Effect of eribulin with or without pembrolizumab on progression-free survival for patients with hormone receptor-positive, erbb2-negative metastatic breast cancer: A randomized clinical trial. *JAMA Oncol* 6, 10 (Oct 2020), 1598–1605
87. LOSK, K., FREEDMAN, R. A., LAWS, A., KANTOR, O., MITTENDORF, E. A., TAN-WASIELEWSKI, Z., TRIPPA, L., LIN, N. U., WINER, E. P., AND KING, T. A. Oncotype dx testing in node-positive breast

- cancer strongly impacts chemotherapy use at a comprehensive cancer center. *Breast Cancer Research and Treatment* 185, 1 (2021), 215–227
88. LAUFFENBURGER, J. C., ISAAC, T., TRIPPA, L., KELLER, P., ROBERTSON, T., GLYNN, R. J., SEQUIST, T. D., KIM, D. H., FONTANET, C. P., CASTONGUAY, E. W. B., HAFF, N., BARLEV, R. A., MAHESRI, M., GOPALAKRISHNAN, C., AND CHOUDHRY, N. K. Rationale and design of the novel uses of adaptive designs to guide provider engagement in electronic health records (nudge-ehr) pragmatic adaptive randomized trial: a trial protocol. *Implementation Science* 16, 1 (2021), 9
 89. VENTZ, S., BACALLADO, S., RAHMAN, R., TOLANEY, S., SCHOENFELD, J. D., ALEXANDER, B. M., AND TRIPPA, L. The effects of releasing early results from ongoing clinical trials. *Nature communications* 12, 1 (2021), 1–7
 90. TAHRI, S., MOUHIEDDINE, T. H., REDD, R. A., LAMPE, L. M., NILSSON, K. I., EL-KHOURY, H., SU, N. K., NASSAR, A. H., ADIB, E., BINDRA, G., ABOU ALAIWI, S., TRIPPA, L., STEENSMA, D. P., CASTILLO, J., TREON, S. P., GHOBRIAL, I. M., AND SPERLING, A. S. Clonal hematopoiesis is associated with increased risk of progression of asymptomatic waldenström macroglobulinemia. *Blood Adv* (Nov 2021)
 91. BACALLADO, S., FAVARO, S., POWER, S., AND TRIPPA, L. Perfect sampling of the posterior in the hierarchical pitman–yor process. *Bayesian Analysis* 1, 1 (2021), 1–25
 92. DE VITO, R., BELLIO, R., TRIPPA, L., AND PARMIGIANI, G. Bayesian multi-study factor analysis for high-throughput biological data. *The Annals of Applied Statistics* 15, 4 (2021), 1723–1741
 93. RUSSO, M., VENTZ, S., WANG, V., AND TRIPPA, L. Inference in response-adaptive clinical trials when the enrolled population varies over time. *Biometrics* (2021)
 94. VENTZ, S., COMMENT, L., LOUV, B., RAHMAN, R., WEN, P. Y., ALEXANDER, B. M., AND TRIPPA, L. The use of external control data for predictions and futility interim analyses in clinical trials. *Neuro-oncology* (2021)
 95. GUGLIELMETTI, L., ARDIZZONI, E., ATGER, M., BAUDIN, E., BERIKOVA, E., BONNET, M., CHANG, E., CLOEZ, S., COIT, J. M., COX, V., DE JONG, B. C., DELIFER, C., DO, J. M., TOZZI, D. D. S., DUCHER, V., FERLAZZO, G., GOUILLOU, M., KHAN, A., KHAN, U., LACHENAL, N., LAHOOD, A. N., LECCA, L., MAZMANIAN, M., MCILLERON, H., MOSCHIONI, M., O'BRIEN, K., OKUNBOR, O., OYEWUSI, L., PANDA, S., PATIL, S. B., PHILLIPS, P. P. J., PICHON, L., RUPASINGHE, P., RICH, M. L., SALUHUDDIN, N., SEUNG, K. J., TAMIRAT, M., TRIPPA, L., CELLAMARE, M., VELÁSQUEZ, G. E., WASSERMAN, S., ZIMETBAUM, P. J., VARAINE, F., AND MITNICK, C. D. Evaluating newly approved drugs for multidrug-resistant tuberculosis (endtb): study protocol for an adaptive, multi-country randomized controlled trial. *Trials* 22, 1 (Sep 2021), 651
 96. BARROSO-SOUSA, R., VAZ-LUIS, I., DI MEGLIO, A., HU, J., LI, T., REES, R., SINCLAIR, N., MILISITS, L., LEONE, J. P., CONSTANTINE, M., FAGGEN, M., BRICCETTI, F., BLOCK, C., PARTRIDGE, A., BURSTEIN, H., WAKS, A. G., TAYOB, N., TRIPPA, L., TOLANEY, S. M., HASSETT, M. J., WINER, E. P., AND LIN, N. U. Prospective study testing a simplified paclitaxel premedication regimen in patients with early breast cancer. *Oncologist* 26, 11 (Nov 2021), 927–933
 97. ARFÈ, A., ALEXANDER, B., AND TRIPPA, L. Optimality of testing procedures for survival data in the nonproportional hazards setting. *Biometrics* 77, 2 (2021), 587–598
 98. RAHMAN, R., VENTZ, S., MCDUNN, J., LOUV, B., REYES-RIVERA, I., POLLEY, M.-Y. C., MERCHANT, F., ABREY, L. E., ALLEN, J. E., AGUILAR, L. K., AGUILAR-CORDOVA, E., ARONS, D., TANNER, K.,

- BAGLEY, S., KHASRAW, M., CLOUGHESY, T., WEN, P. Y., ALEXANDER, B. M., AND TRIPPA, L. Leveraging external data in the design and analysis of clinical trials in neuro-oncology. *Lancet Oncol* 22, 10 (Oct 2021), e456–e465
99. TABRIZI, S., TRIPPA, L., CAGNEY, D., AIZER, A. A., TANGUTURI, S., VENTZ, S., FELL, G., BELLON, J. R., MAMON, H., NGUYEN, P. L., D'AMICO, A. V., HAAS-KOGAN, D., ALEXANDER, B. M., AND RAHMAN, R. Assessment of Simulated SARS-CoV-2 Infection and Mortality Risk Associated With Radiation Therapy Among Patients in 8 Randomized Clinical Trials. *JAMA Network Open* 4, 3 (03 2021), e213304–e213304
 100. TOLANEY, S. M., TAYOB, N., DANG, C., YARDLEY, D. A., ISAKOFF, S. J., VALERO, V., FAGGEN, M., MULVEY, T., BOSE, R., HU, J., WECKSTEIN, D., WOLFF, A. C., REEDER-HAYES, K., RUGO, H. S., RAMASWAMY, B., ZUCKERMAN, D., HART, L., GADI, V. K., CONSTANTINE, M., CHENG, K., BRICCETTI, F., SCHNEIDER, B., GARRETT, A. M., MARCOM, K., ALBAIN, K., DEFUSCO, P., TUNG, N., ARDMAN, B., NANDA, R., JANKOWITZ, R. C., RIMAWI, M., ABRAMSON, V., POHLMANN, P. R., VAN POZNAK, C., FORERO-TORRES, A., LIU, M., RUDDY, K., ZHENG, Y., ROSENBERG, S. M., GELBER, R. D., TRIPPA, L., BARRY, W., DEMEO, M., BURSTEIN, H., PARTRIDGE, A., WINER, E. P., AND KROP, I. Adjuvant trastuzumab emtansine versus paclitaxel in combination with trastuzumab for stage i her2-positive breast cancer (atempt): A randomized clinical trial. *J Clin Oncol* 39, 21 (Jul 2021), 2375–2385
 101. BARROSO-SOUSA, R., KEENAN, T. E., LI, T., TAYOB, N., TRIPPA, L., PASTORELLO, R. G., RICHARDSON III, E. T., DILLON, D., AMOOZGAR, Z., OVERMOYER, B., SCHNITT, S. J., WINER, E. P., MITTENDORF, E. A., VAN ALLEN, E., DUDA, D. G., AND TOLANEY, S. M. Nivolumab in combination with cabozantinib for metastatic triple-negative breast cancer: a phase ii and biomarker study. *npj Breast Cancer* 7, 1 (2021), 110
 102. FELL, G., REDD, R. A., VANDERBEEK, A. M., RAHMAN, R., LOUV, B., MCDUNN, J., ARFÈ, A., ALEXANDER, B. M., VENTZ, S., AND TRIPPA, L. Kmdata: a curated database of reconstructed individual patient-level data from 153 oncology clinical trials. *Database* 2021 (2021)(SV and LT co-last authors)
 103. FILHO, O. M., VIALE, G., STEIN, S., TRIPPA, L., YARDLEY, D. A., MAYER, I. A., ABRAMSON, V. G., ARTEAGA, C. L., SPRING, L. M., WAKS, A. G., WRABEL, E., DEMEO, M. K., BARDIA, A., DELL'ORTO, P., RUSSO, L., KING, T. A., POLYAK, K., MICHOR, F., WINER, E. P., AND KROP, I. E. Impact of her2 heterogeneity on treatment response of early-stage her2-positive breast cancer: Phase ii neoadjuvant clinical trial of t-dm1 combined with pertuzumab. *Cancer Discov* 11, 10 (Oct 2021), 2474–2487
 104. EL-KHOURY, H., LEE, D. J., ALBERGE, J.-B., REDD, R., CEA-CURRY, C. J., PERRY, J., BARR, H., MURPHY, C., SAKRIKAR, D., BARNIDGE, D., KARLSON, E., TRIPPA, L., REBBECK, T., GETZ, G., MARINAC, C., AND GHOBRIAL, I. Prevalence of monoclonal gammopathies including an age-related monoclonal gammopathy of indeterminate potential (mgip) in a racially diverse us population screened by mass spectrometry. *Accepted, Lancet Haematology* (2022)
 105. VENTZ, S., BACALLADO, S., RAHMAN, R., SCHOENFELD, J. D., ALEXANDER, B. M., AND TRIPPA, L. The design and evaluation of hybrid controlled trials that leverage external data and randomization. *Arxiv and Invited minor revision, Nature communications* (2021)
 106. VENTZ, S., AND TRIPPA, L. Bayesian multi-arm de-intensification designs. *Invited resubmission, Bayesian Analysis* (2021)
 107. BUSTOROS, M., ANAND, S., SKLAVENTIS-PISTOFIDIS, R., REDD, R., BOYLE, E. M., ZHITOMIRSKY, B., DUNFORD, A. J., TAI, Y.-T., CHAVDA, S. J., BOEHNER, C., NEUSE, C. J., RAHMAT, M., DUTTA, A.,

- CASNEUF, T., VERONA, R., KASTRITIS, E., TRIPPA, L., STEWART, C., WALKER, B. A., DAVIES, F. E., DIMOPOULOS, M.-A., BERGSAGEL, L., YONG, K., MORGAN, G. J., AGUET, F., GETZ, G., AND GHOBRIAL, I. M. Genetic subtypes of smoldering multiple myeloma are associated with distinct pathogenic phenotypes and clinical outcomes. *bioRxiv ACCEPTED Nature Communications* (2021)
108. BONSAGLIO, M., FORTINI, S., VENTZ, S., AND TRIPPA, L. Approximating the operating characteristics of bayesian uncertainty directed trial designs. *arXiv preprint arXiv:2105.11177 ACCEPTED Journal of Statistical Planning and Inference* (2021)
109. KONISHI, Y., SKLAVENTIS-PISTOFIDIS, R., YUE, H., FERRARI, F., REDD, R. A., LIGHTBODY, E. D., RUSSO, M., PERRY, J., HOROWITZ, E., JUSTIS, A. V., SHAYEGH, N. A., SAVELL, A., PRESCOTT, J., VARMEH, S., NOWAK, R. P., HAMILTON, M., AUCLAIR, D., MARINAC, C. R., TRIPPA, L., FISCHER, E. S., AND GHOBRIAL, I. M. Attenuated response to sars-cov-2 vaccine in patients with asymptomatic precursor stages of multiple myeloma and waldenstrom macroglobulinemia. *Cancer Cell* 40, 1 (Jan 2022), 6–8
110. THOMAS, E. G., TRIPPA, L., BRAUN, D., PARMIGIANI, G., AND DOMINICI, F. A bayesian multi-outcome analysis of fine particulate matter and cardiorespiratory hospitalizations. *ACCEPTED Epidemiology* (2022)
111. MASOERO, L., THOMAS, E., PARMIGIANI, G., TYEKUCHEVA, S., AND TRIPPA, L. Cross-study replicability in cluster analysis. *arxiv: 2202.01910 - invited minor revision - Statistical Science* (2022)
112. GUAN, Z., PARMIGIANI, G., BRAUN, D., AND TRIPPA, L. Prediction of hereditary cancers using neural networks. *arXiv preprint arXiv:2106.13682 ACCEPTED Annals of Applied Statistics* (2021)(DB and LT co-last authors)
113. Romualdo Barroso-Sousa, Paolo Tarantino, Nabihah Tayob, Chau Dang, Denise A Yardley, Steven J Isakoff, Vicente Valero, Meredith Faggen, Therese Mulvey, Ron Bose, Jiani Hu, Douglas Weckstein, Antonio C Wolff, Katherine Reeder-Hayes, Hope S Rugo, Bhuvaneshwari Ramaswamy, Dan Zuckerman, Lowell Hart, Vijayakrishna K Gadi, Michael Constantine, Kit Cheng, Frederick Briccetti, Bryan Schneider, Audrey Merrill Garrett, Kelly Marcom, Kathy Albain, Patricia DeFusco, Nadine Tung, Blair Ardman, Rita Nanda, Rachel C Jankowitz, Mothaffar Rimawi, Vandana Abramson, Paula R Pohlmann, Catherine Van Poznak, Andres Forero-Torres, Minetta Liu, Kathryn J Ruddy, Yue Zheng, Shoshana M Rosenberg, Richard D Gelber, Lorenzo Trippa, William Barry, Michelle DeMeo, Harold Burstein, Ann Partridge, Eric P Winer, Ian Krop, Sara M Tolaney, Cardiac outcomes of subjects on adjuvant trastuzumab emtansine vs paclitaxel in combination with trastuzumab for stage I HER2-positive breast cancer (ATEMPT) study (TBCRC033): a randomized controlled trial. *NPJ Breast Cancer* (2022)
114. Grabski, I. N., De Vito, R., Trippa, L., and Parmigiani, G. (2022). Bayesian combinatorial multi-study factor analysis. *arXiv:2007.12616 - invited minor revision, The Annals of Applied Statistics*.

Other Manuscripts: Book Chapters, Comments and Conference Proceedings

1. PETRONE, S., AND TRIPPA, L. Bayesian modeling via nested random partitions. In *S. Co. 2009. Sixth Conference. Complex Data Modeling and Computationally Intensive Statistical Methods for Estimation and Prediction* (2009), Maggioli Editore
2. TRIPPA, L., ROSNER, G. L., AND MÜLLER, P. Rejoinder. *Biometrics* (2012), 224–225

3. PARMIGIANI, G., AND TRIPPA, L. Comment on Article by Müller and Mitra. *Bayesian Analysis* (2013), 346–347
4. TRIPPA, L., LEE, E. Q., WEN, P. Y., BATCHELOR, T. T., CLOUGHESY, T., PARMIGIANI, G., AND ALEXANDER, B. M. Reply to B. Freidlin et al. *Journal of Clinical Oncology* (2013), 970–971
5. TRIPPA, L. Bayesian adaptive trials. *Proceedings, Scientific Meeting of The Italian Statistical Society, SIS 2014. Cagliari (Italy)*
6. PARMIGIANI, G., BOCA, S., DING, J., AND TRIPPA, L. Statistical tools and r software for cancer driver probabilities. In *Gene Function Analysis*. Springer, 2014, pp. 113–134
7. JO, S., LEE, J., PAGE, G., QUINTANA, F., TRIPPA, L., AND MÜLLER, P. Spatial species sampling and product partition models. In *Nonparametric Bayesian inference in biostatistics*. Springer, 2015, pp. 359–375
8. TRIPPA, L., AND PARMIGIANI, G. Comment to "Bayesian Nonparametric Estimation for Dynamic Treatment Regimes With Sequential Transition Times". *Journal of the American Statistical Association* (2016)
9. LEE, J. J., AND TRIPPA, L. Adaptive clinical trial designs in oncology. *Cancer Clinical Trials: Current and Controversial Issues in Design and Analysis - editors: George SL, Wang X, Pang H - CRC Press* (2016)
10. PAULON, G., TRIPPA, L., AND MÜLLER, P. Discussion of: Bayesian cluster analysis, point estimation and credible balls. *Bayesian Analysis* (2018)
11. SCHOENFELD, J. D., FELL, G., HADDAD, R. I., AND TRIPPA, L. Reply to" keynote 48: Is it really for everyone?". *Oral Oncology* (2020), 105108–105108
12. TRIPPA, L., AND BACALLADO, S. Empirical Evaluations of Clinical Trial Designs. *JAMA network open ACCEPTED* (2022)